

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Sedrani et al.

APPLICATION NO: 09/585743

FILED: June 02, 2000

FOR: RAPAMYCIN ASSAY.

Art Unit: 1614

Examiner: Haq. Shafiqui

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ Supplemental to the Information Disclosure Statement filed February 5, 2001.

☒ Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO/SB/08A/B.

☐ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A/B form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corporation
One Health Plaza Bldg. 101
East Hanover, NJ 07936
617-871-8469

Date: June 17, 2011

/Christine McCormack/

Christine McCormack
Attorney for Applicant
Reg. No. 61,331

(617) 871-8486